Galapagos ( (GB:0JXZ) ) has provided an update.
Galapagos NV announced its participation in two major investor conferences in March, highlighting its commitment to engaging with stakeholders and showcasing its innovative approaches in biotechnology. The company’s presentations at the TD Cowen 45th Annual Healthcare Conference and the Barclays 27th Annual Global Healthcare Conference will be available via live webcast, emphasizing its strategic efforts to maintain transparency and communication with investors and the broader market.
More about Galapagos
Galapagos NV is a biotechnology company with operations in Europe and the US, focusing on improving patient outcomes through innovative science. The company addresses major unmet medical needs by developing a broad pipeline of best-in-class medicines, leveraging deep scientific knowledge, technology, and collaborations. Galapagos is committed to challenging the status quo and shaping the future of healthcare, with capabilities ranging from lab research to patient delivery, including a decentralized cell therapy manufacturing platform.
YTD Price Performance: -2.73%
Average Trading Volume: 8,028
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €1.69B
For detailed information about 0JXZ stock, go to TipRanks’ Stock Analysis page.